(Q43718269)

26 November 2017

title

Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats (English)

1 reference

26 November 2017

0 references

Carrascosa JM

1

1 reference

26 November 2017

Molero JC

2

1 reference

26 November 2017

Fermín Y

3

1 reference

26 November 2017

Martínez C

4

1 reference

26 November 2017

Andrés A

5

1 reference

26 November 2017

Satrústegui J

6

1 reference

26 November 2017

publication date

1 August 2001

1 reference

Diabetes, Obesity and Metabolism

26 November 2017

published in

1 reference

26 November 2017

volume

3

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

240-248

1 reference

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Postprandial hyperglycaemia and alpha-glucosidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Metabolic abnormalities in the genetically obese and diabetic Otsuka Long-Evans Tokushima Fatty rat can be prevented and reversed by alpha-glucosidase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

Effects of an α-Glucosidase Inhibitor, Acarbose, on Blood Glucose and Serum Lipids in Streptozotocin-Induced Diabetic Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00102.X

10.1046/J.1463-1326.2001.00102.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference